KaloBios Pharmaceuticals, Inc. announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's board of directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.50% |
|
-99.50% | -99.92% |
05-01 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-99.92% | 119 | |
+2.15% | 95.18B | |
-4.34% | 37.55B | |
+75.79% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B | |
+6.22% | 9.09B |
- Stock Market
- Equities
- HGEN.Q Stock
- News Humanigen, Inc.
- KaloBios Pharmaceuticals, Inc. Announces Management Changes